Literature DB >> 11196696

IL-6 promoter polymorphisms in rheumatoid arthritis.

M Pascual1, A Nieto, L Matarán, A Balsa, D Pascual-Salcedo, J Martín.   

Abstract

We investigated the possible association between the IL-6 promoter polymorphisms, at positions -622 and -174, and susceptiblity to, and/or outcome of, rheumatoid arthritis (RA). A total of 163 patients with RA and 157 healthy controls were genotyped for IL-6 using a PCR-RFLP method. The -622 and -174 alleles were in complete linkage disequilibrium. No difference was observed in the distribution of IL-6 promoter genotype or allele frequencies between RA patients and controls. However, a significant difference in the mean age at disease onset between IL-6 genotypes was observed. The present data appear to rule out an important role of IL-6 promoter polymorphisms in the susceptibility to RA. However, IL-6 genotypes may contribute to the pathogenesis of the disease by influencing the age at disease onset.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11196696     DOI: 10.1038/sj.gene.6363677

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  20 in total

1.  A posteriori evaluation of effects attributed to IL-6 gene regulatory variants.

Authors:  Philipp G Sand
Journal:  Inflamm Res       Date:  2012-06-27       Impact factor: 4.575

2.  Lack of association between IL-6 gene polymorphisms and rheumatoid arthritis in Turkish population.

Authors:  A Arman; A Coker; O Sarioz; N Inanc; H Direskeneli
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

3.  Combined effect of cytokine gene polymorphisms on end-stage knee osteoarthritis from Chinese Han population.

Authors:  Chengyu Lv; Xiaoyan Xu; Jinqing Wang; Zhongyi Zhang; Dianliang Zhang; Chuanyou Guo; Chengxin Geng; Yunbo Sun
Journal:  Rheumatol Int       Date:  2011-11-26       Impact factor: 2.631

4.  -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.

Authors:  Ivan Jančić; Nevena Arsenović-Ranin; Mirjana Sefik-Bukilica; Sladjana Zivojinović; Nemanja Damjanov; Vesna Spasovski; Sanja Srzentić; Biljana Stanković; Sonja Pavlović
Journal:  Rheumatol Int       Date:  2012-12-12       Impact factor: 2.631

Review 5.  Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.

Authors:  Lili Magyari; Dalma Varszegi; Erzsebet Kovesdi; Patricia Sarlos; Bernadett Farago; Andras Javorhazy; Katalin Sumegi; Zsolt Banfai; Bela Melegh
Journal:  World J Orthop       Date:  2014-09-18

Review 6.  gp130 at the nexus of inflammation, autoimmunity, and cancer.

Authors:  J S Silver; C A Hunter
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

7.  Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.

Authors:  Heiko Schotte; Hartmut Schmidt; Markus Gaubitz; Susanne Drynda; Jörn Kekow; Peter Willeke; Bernhard Schlüter
Journal:  Clin Rheumatol       Date:  2015-11-03       Impact factor: 2.980

8.  TGF-β1 limits the onset of innate lung inflammation by promoting mast cell-derived IL-6.

Authors:  Kirthana Ganeshan; Laura K Johnston; Paul J Bryce
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

9.  -174G>C interleukin-6 gene polymorphism in Tunisian patients with coronary artery disease.

Authors:  Lakhdar Ghazouani; Nesrine Abboud; Sonia Ben Hadj Khalifa; Faouzi Added; Ali Ben Khalfallah; Brahim Nsiri; Mounira Mediouni; Touhami Mahjoub
Journal:  Ann Saudi Med       Date:  2011 Jan-Feb       Impact factor: 1.526

10.  Gene polymorphisms and pharmacogenetics in rheumatoid arthritis.

Authors:  Ignacio Rego-Pérez; Mercedes Fernández-Moreno; Francisco J Blanco
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.